celecoxib has been researched along with Sensitivity and Specificity in 41 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial." | 9.14 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009) |
| "In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM)." | 9.12 | Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. ( Giglio, P; Groves, MD; Hess, K; Jochec, J; Levin, VA; Puduvalli, VK; Yung, WK, 2006) |
| "The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)." | 7.73 | Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006) |
| " This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg." | 5.33 | Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006) |
| "We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial." | 5.14 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009) |
| "In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM)." | 5.12 | Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. ( Giglio, P; Groves, MD; Hess, K; Jochec, J; Levin, VA; Puduvalli, VK; Yung, WK, 2006) |
| "In patients with multiple comorbidities, naproxen- and ibuprofen-containing regimens are more effective and cost-effective in managing OA pain than opioids, celecoxib or SOC." | 3.83 | Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. ( Collins, JE; Hunter, DJ; Jordan, JM; Katz, JN; Losina, E; Paltiel, AD; Smith, SR; Solomon, DH; Suter, LG; Yelin, E, 2016) |
| "High-dose celecoxib (2 g/kg), a selective COX-2 inhibitor, did not cause hearing loss or tinnitus in Sprague Dawley rats within 48 hours of administration." | 3.81 | Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats. ( Feng, Y; Li, B; Su, K; Xia, L; Yang, G; Yin, S, 2015) |
| "The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)." | 3.73 | Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006) |
| "To analyse the cost of celecoxib (selective cyclo-oxygenase-2 inhibitor) and conventional NSAID regimens for the treatment of osteoarthritis and rheumatoid arthritis from the perspective of a public health organization in Hong Kong." | 3.71 | Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. ( Chan, FK; Chan, TY; Lau, WH; Lee, KK; You, JH, 2002) |
| "Celecoxib was given at 400 mg twice daily." | 2.73 | Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. ( Carroll, M; Frankel, P; Ruel, C; Smith-Powell, L; Synold, TW; Twardowski, PW; VanBalgooy, J, 2008) |
| "In celecoxib-treated subjects, 2." | 2.71 | A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. ( Cryer, B; Kimmey, MB; Riff, DS; Rothstein, RI; Scheiman, JM; Wolfe, MM, 2004) |
| " The method is suitable not only for the estimation of active ingredients in pharmaceutical dosage forms but also in vitro estimations in human plasma." | 1.33 | Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. ( Meena, S; Nagaraju, D; Rao, AR; Rao, RN, 2005) |
| " This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg." | 1.33 | Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006) |
| "Indomethacin (3 mg/kg) was then compared to celecoxib (4." | 1.32 | Indomethacin and celecoxib improve tendon healing in rats. ( Aspenberg, P; Bylander, B; Forslund, C, 2003) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| "Celecoxib-treated mice also developed fewer tumors (1." | 1.32 | The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. ( Daskalakis, C; Flynn, J; Gallatig, K; Lanza-Jacoby, S; Masferrer, JL; Miller, S; Russo, IH; Sembhi, H; Zweifel, BS, 2003) |
| "Celecoxib treatment results in a reasonable cost-effectiveness ratio for patients with OA of the knee." | 1.32 | Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. ( Chen, LS; Chen, SC; Chen, WJ; Hou, SM; Lai, MS; Wang, CT; Yen, ZS, 2004) |
| "Celecoxib itself seems to be a valuable alternative drug in NSAID-sensitive patients." | 1.31 | Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. ( Boehncke, WH; Kaufmann, R; Kleinhans, M; Linzbach, L; Zedlitz, S, 2002) |
| "Celecoxib is a cyclooxygenase-2 specific inhibitor, that has been recently and intensively prescribed as an anti-inflammatory drug in rheumatic osteoarthritis." | 1.31 | Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. ( Abdel-Hamid, M; Hamza, H; Novotny, L, 2001) |
| " After validation, the method was used to study the pharmacokinetic profile of celecoxib following administration of a single oral dose (200 mg) in 12 healthy volunteers." | 1.31 | Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ( Brune, K; Gillich, M; Mundkowski, R; Pahl, A; Werner, D; Werner, U, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (75.61) | 29.6817 |
| 2010's | 8 (19.51) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Be Rziņš, KR | 1 |
| Fraser-Miller, SJ | 1 |
| Rades, T | 1 |
| Gordon, KC | 1 |
| Maneesh, MU | 1 |
| Ahmed, SS | 1 |
| Pasha, TY | 1 |
| Ramesh, B | 1 |
| Majumder, M | 1 |
| Ali, RB | 1 |
| Omrani, R | 1 |
| Akacha, AB | 1 |
| Dziri, C | 1 |
| El May, MV | 1 |
| Su, SC | 1 |
| Tanimoto, K | 1 |
| Tanne, Y | 1 |
| Kunimatsu, R | 1 |
| Hirose, N | 1 |
| Mitsuyoshi, T | 1 |
| Okamoto, Y | 1 |
| Tanne, K | 1 |
| Li, B | 1 |
| Su, K | 1 |
| Yang, G | 1 |
| Feng, Y | 1 |
| Xia, L | 1 |
| Yin, S | 1 |
| Katz, JN | 1 |
| Smith, SR | 1 |
| Collins, JE | 1 |
| Solomon, DH | 1 |
| Jordan, JM | 1 |
| Hunter, DJ | 2 |
| Suter, LG | 1 |
| Yelin, E | 1 |
| Paltiel, AD | 1 |
| Losina, E | 1 |
| Manesh, KM | 1 |
| Santhosh, P | 1 |
| Komathi, S | 1 |
| Kim, NH | 1 |
| Park, JW | 1 |
| Gopalan, AI | 1 |
| Lee, KP | 1 |
| Chan, AT | 1 |
| Zauber, AG | 1 |
| Hsu, M | 1 |
| Breazna, A | 1 |
| Rosenstein, RB | 1 |
| Eagle, CJ | 1 |
| Hawk, ET | 1 |
| Bertagnolli, MM | 1 |
| Praça, FS | 1 |
| Bentley, MV | 1 |
| Lara, MG | 1 |
| Pierre, MB | 1 |
| González-Mateo, GT | 1 |
| Aroeira, LS | 1 |
| López-Cabrera, M | 1 |
| Ruiz-Ortega, M | 1 |
| Ortiz, A | 1 |
| Selgas, R | 1 |
| Choi, NK | 1 |
| Chang, Y | 1 |
| Kim, JY | 1 |
| Choi, YK | 1 |
| Park, BJ | 1 |
| Kleinhans, M | 1 |
| Linzbach, L | 1 |
| Zedlitz, S | 1 |
| Kaufmann, R | 1 |
| Boehncke, WH | 1 |
| Störmer, E | 1 |
| Bauer, S | 1 |
| Kirchheiner, J | 1 |
| Brockmöller, J | 1 |
| Roots, I | 1 |
| You, JH | 1 |
| Lee, KK | 1 |
| Chan, TY | 1 |
| Lau, WH | 1 |
| Chan, FK | 2 |
| Wang, Z | 1 |
| Fuentes, CF | 1 |
| Shapshay, SM | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Forslund, C | 1 |
| Bylander, B | 1 |
| Aspenberg, P | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Lanza-Jacoby, S | 1 |
| Miller, S | 1 |
| Flynn, J | 1 |
| Gallatig, K | 1 |
| Daskalakis, C | 1 |
| Masferrer, JL | 1 |
| Zweifel, BS | 1 |
| Sembhi, H | 1 |
| Russo, IH | 1 |
| Hausman, N | 2 |
| Beharry, KD | 1 |
| Nishihara, KC | 1 |
| Akmal, Y | 2 |
| Asrat, T | 2 |
| Beharry, K | 1 |
| Nishihara, K | 1 |
| Stavitsky, Y | 1 |
| Scheiman, JM | 1 |
| Cryer, B | 1 |
| Kimmey, MB | 1 |
| Rothstein, RI | 1 |
| Riff, DS | 1 |
| Wolfe, MM | 1 |
| Yen, ZS | 1 |
| Lai, MS | 1 |
| Wang, CT | 1 |
| Chen, LS | 1 |
| Chen, SC | 1 |
| Chen, WJ | 1 |
| Hou, SM | 1 |
| Rao, RN | 1 |
| Meena, S | 1 |
| Nagaraju, D | 1 |
| Rao, AR | 1 |
| Aimbire, F | 1 |
| Albertine, R | 1 |
| de Magalhães, RG | 1 |
| Lopes-Martins, RA | 1 |
| Castro-Faria-Neto, HC | 1 |
| Zângaro, RA | 1 |
| Chavantes, MC | 1 |
| Pacheco, MT | 1 |
| Greene, AK | 1 |
| Alwayn, IP | 1 |
| Nose, V | 1 |
| Flynn, E | 1 |
| Sampson, D | 1 |
| Zurakowski, D | 1 |
| Folkman, J | 1 |
| Puder, M | 1 |
| Hamama, AK | 1 |
| Ray, J | 1 |
| Day, RO | 1 |
| Brien, JA | 1 |
| Levin, VA | 1 |
| Giglio, P | 1 |
| Puduvalli, VK | 1 |
| Jochec, J | 1 |
| Groves, MD | 1 |
| Yung, WK | 1 |
| Hess, K | 1 |
| Hui, AY | 1 |
| Leung, WK | 1 |
| Chan, HL | 1 |
| Go, MY | 1 |
| Chan, KK | 1 |
| Tang, BD | 1 |
| Chu, ES | 1 |
| Sung, JJ | 1 |
| Konturek, PC | 1 |
| Rembiasz, K | 1 |
| Burnat, G | 1 |
| Konturek, SJ | 1 |
| Tusinela, M | 1 |
| Bielanski, W | 1 |
| Rehfeld, J | 1 |
| Karcz, D | 1 |
| Hahn, E | 1 |
| Hsieh, YH | 1 |
| Lin, SJ | 1 |
| Chen, SH | 1 |
| Shpitz, B | 1 |
| Giladi, N | 1 |
| Sagiv, E | 1 |
| Lev-Ari, S | 1 |
| Liberman, E | 1 |
| Kazanov, D | 1 |
| Arber, N | 1 |
| Futagami, S | 1 |
| Suzuki, K | 1 |
| Hiratsuka, T | 1 |
| Shindo, T | 1 |
| Hamamoto, T | 1 |
| Tatsuguchi, A | 1 |
| Ueki, N | 1 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Wada, K | 1 |
| Miyake, K | 1 |
| Gudis, K | 1 |
| Tsukui, T | 1 |
| Sakamoto, C | 1 |
| Loyd, M | 1 |
| Rublee, D | 1 |
| Jacobs, P | 1 |
| Twardowski, PW | 1 |
| Smith-Powell, L | 1 |
| Carroll, M | 1 |
| VanBalgooy, J | 1 |
| Ruel, C | 1 |
| Frankel, P | 1 |
| Synold, TW | 1 |
| Tibble, JA | 1 |
| Sigthorsson, G | 1 |
| Foster, R | 1 |
| Bjarnason, I | 1 |
| Abdel-Hamid, M | 1 |
| Novotny, L | 1 |
| Hamza, H | 1 |
| Werner, U | 1 |
| Werner, D | 1 |
| Pahl, A | 1 |
| Mundkowski, R | 1 |
| Gillich, M | 1 |
| Brune, K | 1 |
| Schönberger, F | 1 |
| Heinkele, G | 1 |
| Mürdter, TE | 1 |
| Brenner, S | 1 |
| Klotz, U | 1 |
| Hofmann, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[NCT00007189] | Phase 3 | 2,625 participants | Interventional | 2001-01-31 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study[NCT01417130] | 1,650 participants (Anticipated) | Observational | 2009-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
5 trials available for celecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Celecoxib; Colorectal Neopla | 2009 |
A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.
Topics: Adolescent; Adult; Aged; Celecoxib; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bli | 2004 |
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Di | 2006 |
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Cyclophos | 2008 |
35 other studies available for celecoxib and Sensitivity and Specificity
| Article | Year |
|---|---|
Low-Frequency Raman Spectroscopy as an Avenue to Determine the Transition Temperature of β- and γ-Relaxation in Pharmaceutical Glasses.
Topics: Calorimetry, Differential Scanning; Celecoxib; Cimetidine; Indoles; Pharmaceutical Preparations; Phe | 2022 |
A Simple Bioanalytical Method for Simultaneous Estimation of Amlodipine and Celecoxib in Rat Plasma by High Performance Liquid Chromatography.
Topics: Amlodipine; Animals; Celecoxib; Chromatography, High Pressure Liquid; Female; Linear Models; Male; R | 2021 |
Development and validation of a colorimetric method for the quantitative analysis of thioamide derivatives.
Topics: Calibration; Celecoxib; Chemical Fractionation; Colorimetry; Cystine; Dithionitrobenzoic Acid; Human | 2019 |
Celecoxib exerts protective effects on extracellular matrix metabolism of mandibular condylar chondrocytes under excessive mechanical stress.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Celecoxib; Cells, Cultured; Cho | 2014 |
Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Topics: Animals; Auditory Threshold; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Re | 2015 |
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Com | 2016 |
Electrochemical detection of celecoxib at a polyaniline grafted multiwall carbon nanotubes modified electrode.
Topics: Adsorption; Aniline Compounds; Celecoxib; Electrochemistry; Electrodes; Electrolytes; Electron Trans | 2008 |
Celecoxib determination in different layers of skin by a newly developed and validated HPLC-UV method.
Topics: Animals; Celecoxib; Chemical Fractionation; Chromatography, High Pressure Liquid; Dermis; Epidermis; | 2011 |
Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?
Topics: Animals; Celecoxib; Dialysis Solutions; Disease Models, Animal; Enalapril; Female; Humans; Male; Mic | 2012 |
Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2 | 2011 |
Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; C | 2002 |
Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection.
Topics: Celecoxib; Chromatography, High Pressure Liquid; Humans; Pyrazoles; Reproducibility of Results; Sens | 2003 |
Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele | 2002 |
Cancer "photo-chemoprevention" with pulsed dye laser and celecoxib.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Combined Modality Therapy; Disease Mo | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Indomethacin and celecoxib improve tendon healing in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Sectional S | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Topics: Animals; Biopsy, Needle; Blotting, Western; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, An | 2003 |
Effect of the antenatal administration of celecoxib during the second and third trimesters of pregnancy on prostaglandin, cytokine, and nitric oxide levels in rabbits.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Drug Administration Schedule; Female; Mode | 2003 |
Response of fetal prostanoids, nitric oxide, and ductus arteriosus to the short- and long-term antenatal administration of celecoxib, a selective cyclo-oxygenase-2 inhibitor, in the pregnant rabbit.
Topics: Analysis of Variance; Animals; Celecoxib; Cyclooxygenase Inhibitors; Drug Administration Schedule; D | 2003 |
Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; F | 2004 |
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.
Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lacto | 2005 |
Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat.
Topics: Animals; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Celecoxib; Chemotaxis, Leukocyte; | 2005 |
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
Topics: Animals; Biopsy, Needle; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Immunohistoch | 2005 |
Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography.
Topics: Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazo | 2005 |
Effect of celecoxib on experimental liver fibrosis in rat.
Topics: Animals; Biopsy, Needle; Celecoxib; Connective Tissue Growth Factor; Cyclooxygenase 2; Cyclooxygenas | 2006 |
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Topics: Adenocarcinoma; Aged; Apoptosis Regulatory Proteins; Base Sequence; Biomarkers, Tumor; Biopsy, Needl | 2006 |
Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations.
Topics: Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Electrophoresis, Capillary; Human | 2006 |
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biopsy, Needle; C | 2006 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |
An economic model of long-term use of celecoxib in patients with osteoarthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit | 2007 |
Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Membrane Permeability; Cyclooxygen | 2000 |
Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Male; Mass Spectrometry; Pyrazoles; Reproducibility of | 2001 |
Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.
Topics: Administration, Oral; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Celecoxib; Chromatography, Hi | 2002 |
Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection.
Topics: Adult; Aged; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Pyr | 2002 |